FIRST QUARTER 2025 UPDATES, INCLUDING BREAKTHROUGH PHASE 2 DMD STUDY RESULTS

Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed to executing our growth strategy and delivering long-term value. We […]

EARLY 2025 MILESTONES

Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines, establishing a long-term pipeline for our business. We recently reported […]

November 2024 Updates, Highlighting Key Clinical and Business Developments

We are pleased to report several significant milestones that reinforce our mission of working together to provide unique products that improve the quality of patient care. Our latest updates include important research findings, growing Medicaid coverage and expanded product access. In October, we announced new real-world outcomes research comparing Caldolor® to its key competitor – […]